EVIDENCE STARTS WITH US
Largest Body of Prospective Clinical Evidence in LITT
Our sole purpose at Monteris Medical is to create cutting-edge, minimally invasive technology that can forever change patients’ lives for the better. To that end, we continue to build upon our well-established and recognized leadership position in prospective evidence generation for LITT.
NEW STUDY! Only from Monteris.
Published in JAMA Neurology: Largest Cohort to date published on LITT for drug-resistant mesial temporal lobe epilepsy. See the results here >
Post-Market and Randomized Multicenter Clinical Trials
Monteris Medical is the established and recognized leader in LITT for the brain, setting the benchmark for precision, safety, and evidence-based outcomes. While LITT is increasingly adopted in neurosurgery, it is critical to recognize that only the NeuroBlate® System from Monteris is supported by an unparalleled foundation of peer-reviewed prospective evidence, demonstrating consistent performance across a wide range of brain pathologies including primary and metastatic brain tumors, radiation necrosis, and drug-resistant epilepsy.
Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate® System NCT02392078
- The first prospective multicenter laser ablation study in the brain.
- More than 1,000 patients enrolled across the U.S., received NeuroBlate, and were followed up to 5 years.
- Outcomes include safety, quality of life, health economics, procedural outcomes, seizure freedom, and survival. Enrollment completed.
Recurrent Brain Metastases after SRS Trial NCT05124912
- The first randomized controlled multicenter study investigating LITT using the NeuroBlate System as an early intervention for radiographically progressive brain metastases.
- Designed to deliver Level I evidence to guide the treatment algorithm for both the recurrent metastatic tumor and radiation necrosis populations following SRS.
- Currently enrolling.
Guidelines and Position Statements
LITT is included in the major neuro-oncology and neurosurgical societies’ guidelines, further supporting its use in oncology and drug-resistant epilepsy.
Investigator Initiated Research Support
Monteris has an active investigator-initiated research program, which allows us to partner with investigators in their LITT early phase research. For more information contact clinicalaffairs@monteris.com.
LEADING EXPERTS DISCUSS LITT EVIDENCE AND MORE
Hear from renowned physicians as they break down the latest published data, case reviews, and share their clinical experience. Visit our video channel to watch full discussions.
Disclosures
Monteris provides technology for neurosurgeons, which allows them to ablate (destroy with heat), brain structures such as brain tumors, radiation necrosis, and epileptic foci. Monteris technology includes the NeuroBlate System, AtamA, and MiniBolt devices, which may be used together to apply the focused laser energy with little or no effect on surrounding healthy tissue. The NeuroBlate System provides clinicians a tool that offers near real-time control and MRI visualization of the therapy during laser ablation treatment.
All brain surgeries carry risk. Possible adverse events include, but are not limited to, hematoma, embolic events, edema, bleeding, cerebral spinal fluid (CSF) leakage, infection, unintended major tissue damage and permanent neurological deficits. Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions and potential adverse events. The intended patients are adults and pediatrics from the age of two years and older. For full prescribing information, please visit monteris.com
Rx Only